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ABSTRACT: S-Allyl cysteine (SAC) is found in garlic and has been reported to exert antidiabetic and antiobesity proper-
ties in drug-induced adult experimental models of metabolic dysfunction, but its potential beneficial effects in high-fruc-
tose diet neonatal rat models have not been determined. This study investigated the potential prophylactic effects of SAC 
in high-fructose diet fed suckling rat pups modelling human neonates fed a high-fructose diet. Four-day-old male (n=32) 
and female (n=32) Wistar rat pups, were randomly assigned to and administered the following treatment regimens daily 
for 15 days: group I, distilled water; group II, 20% fructose solution (FS); group III, SAC; group IV, SAC+FS. The pups’ 
blood glucose, triglyceride, cholesterol, plasma leptin and insulin concentration, liver lipid content, and liver histology 
were determined at termination. In female rat pups, orally administered SAC prevented FS-induced hypoinsulinemia but 
significantly increased (P≤0.05) liver lipid content. Oral administration of SAC significantly increased (P≤0.05) plasma 
insulin concentration and homeostasis model assessment for insulin resistance in the male pups. The potential sexually 
dimorphic effects of SAC (insulinotropic effects in male pups and protection of female pups against fructose-induced hy-
poinsulinemia) suggest that SAC could be potentially exploited as an antidiabetic and insulinotropic agent. Caution should, 
however, be exercised in the use of SAC during suckling as it could result in excessive liver lipid accumulation and in-
sulin resistance. 
Keywords: S-allyl cysteine, neonatal, fructose, insulinotropic 
INTRODUCTION
Globally, approximately 42 million children under the age 
of 5 are classified as being overweight or obese (1). Child-
hood obesity is associated with the development of meta-
bolic derangements such as type II diabetes mellitus (DM 
II), metabolic syndrome (MetS), and non-alcoholic fatty 
liver disease (NAFLD) in childhood or later in adulthood 
(2,3). Sedentary lifestyles and poor dietary habits have 
been identified as the main contributors to the global 
childhood obesity epidemic. The ‘developmental origins 
of health and disease’ theory states that environmental 
and dietary events in perinatal life can temporarily or per-
manently alter an organism’s physiology (4). The phys-
iological alterations can program resistance or suscepti-
bility to disease, and thus dietary events during perinatal 
life may also contribute to the increase in obesity and 
MetS in childhood and adulthood (5). 
Rats are altricial rodents who depend exclusively on the 
dam’s milk during early postnatal (neonatal) develop-
ment, which is equivalent to the last trimester of preg-
nancy in humans (6). The neonatal rat model is thus well 
suited for investigating the effects of early life dietary 
manipulations on the programming of adverse metabolic 
outcomes in early life and later life. Furthermore, during 
suckling (early postnatal), the majority of the physiolog-
ical systems including the endocrine system are imma-
ture (7). Studies using neonatal rat models have shown 
that dietary manipulations during suckling can cause 
temporary or permanent alterations to physiological 
functions and increased susceptibility to disease (4,8,9). 
Importantly the rat’s early postnatal (neonatal) period is 
a feasible target period for investigating prophylactic in-
tervention (pharmacological and ethnomedicinal sub-
stances) against the diet-induced programming of adverse 
metabolic outcomes in perinatal life (4,9). Although there 
are numerous conventional antidiabetic and antiobesity 
pharmacological agents that could be used to prevent di-
et-induced (i.e. high-fructose diet) adverse short- and 
long-term metabolic programming outcomes, an esti-
mated 80% of the global population prefers using plant- 
derived ethnomedicines to treat ailments (10,11). Plant- 
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Fig. 1. Experimental design. DH (con-
trol), 10 mL/kg body mass per day 
distilled water; FS, 10 mL/kg body 
mass per day 20% fructose solution 
(w/v); SAC, 150 mg/kg body mass 
per day S-allyl cysteine; SAC+FS, 150
mg/kg body mass per day S-allyl 
cysteine+10 mL/kg body mass per 
day 20% fructose solution (w/v).
derived ethnomedicines are natural and thus are perceived 
to have fewer or reduced side effects and are considered 
safer than conventional pharmacological agents (10). 
Garlic, Allium sativum, is globally used as a spice and as 
an ethnomedicine. It contains health beneficial phyto-
chemicals such as alliin, diallyl disulphide, and S-allyl 
cysteine (SAC) (12). SAC, a water-soluble organosulphur 
peptide found in abundance in aged garlic preparations, 
has been shown in vitro and in vivo to possess health ben-
eficial properties (13,14). The administration of SAC at 
50∼150 mg/kg body weight was shown to attenuate hy-
perglycaemia, hypoinsulinaemia, hyperlipidaemia, and ox-
idative stress in adult STZ-diabetic rats (14-16). Takemura 
et al. (17) reported that in vivo SAC alleviated hypercho-
lesterolemia and hypertriglyceridemia in non-alcoholic 
fatty liver diseased Otsuka Long-Evans Tokushima male 
rats. In vitro, SAC has been shown to inhibit lipogenesis, 
promote lipid hydrolysis, and upregulate antioxidant en-
zymes (18).
The consumption of a high fructose diet results in an 
increased hepatic lipogenic turnover and the subsequent 
manifestation of various metabolic derangements such 
as dyslipidaemia (hypertriglyceridemia and hypercholes-
terolemia), hyperglycaemia, and insulin and leptin re-
sistance (19,20). This study sought to determine if the 
administration of SAC could protect suckling male and 
female Wistar rats administered 20% fructose solution 
against the development of metabolic derangements by 
specifically determining its effects on body mass, blood 
glucose, triglyceride, and cholesterol concentration, total 
liver lipid, and NAFLD activity score. The pattern of de-
velopment and maturation of physiological systems in 
early life occurs differently in male and females rats, thus 
we also hypothesised that there would be sexually di-
morphic responses to the orally administered treatments. 
MATERIALS AND METHODS
Source of SAC
Reagent grade SAC was procured from ChromaDex (Ir-
vine, CA, USA).
Animals, feeding, and housing 
Four-day-old male (n=32) and female (n=32) suckling 
Wistar rat pups from primiparous dams were used in the 
study. The rat litters were housed in the Central Animal 
Service animal unit with their respective dams and were 
allowed ad libitum suckling of their mother’s milk 
throughout the experiment. Perspex cages for the hous-
ing had stainless steel mesh lids. Bedding made up of 
clean wood shavings was provided and changed twice per 
week. Room temperature was maintained at 24±2oC with 
a 12-h light/dark cycle (lights on from 07:00 h to 19:00 
h). The pups were acclimatised for two days prior to the 
commencement of the experiment. All the experiments 
conducted in the current study complied with interna-
tional laws and policies (NIH Guide for the Care and Use 
of Laboratory Animals). Ethical clearance for the study 
was granted by the Animal Ethics Screening Committee 
(AESC) of the University of Witwatersrand. The AESC 
clearance number was 2015/07/B.
Experimental design 
The pups were randomly allocated to and administered 
one of the following treatment regimens: group I (con-
trol), gavaged with 10 mL/kg body mass/d distilled wa-
ter (DH); group II, gavaged with 10 mL/kg body mass/d 
20% fructose solution w/v (FS); group III, gavaged with 
150 mg/kg body mass/d of SAC dissolved in distilled 
water (10 mL/kg body mass); group IV, SAC+FS (Fig. 
1). The random allocation was such that there were 8 
male and 8 female pups per treatment regimen, and the 
treatment regimens were administered daily for 15 days 
from postnatal day (PND) 6 to 20 days.
The pups were weighed daily using an electronic scale 
(Snowrex Electronic Scale, Clover Scales Pty Ltd., Jo-
hannesburg, South Africa) to monitor body mass and to 
maintain a constant dose of the treatment regimens 
throughout the treatment period.
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Fig. 2. Terminal body masses of the male (A) and female (B) 
rat pups. Data presented as mean±SD (n=8). Terminal body 
masses of male and female rat pups were significantly different 
from induction body masses (***P<0.0001). DH (control), 10 
mL/kg body mass per day distilled water; FS, 10 mL/kg body 
mass per day 20% fructose solution (w/v); SAC, 150 mg/kg body 
mass per day S-allyl cysteine; SAC+FS, 150 mg/kg body mass 
per day S-allyl cysteine+10 mL/kg body mass per day 20% fruc-
tose solution (w/v). PND, postnatal day.
Terminal procedures
Determination of terminal body mass and blood parameters: On 
PND 21, the rat pups’ terminal body masses were deter-
mined, and blood was obtained from the tail vein via pin-
prick and used to determine non-fasted blood glucose 
concentration using a calibrated Contour plus glucome-
ter (Bayer, Isando, South Africa) as per the manufactur-
er’s instructions. The pups were then euthanised by in-
traperitoneal injection with 100 mg/kg body mass of so-
dium pentobarbital (Eutha-naze, Bayer). Following eutha-
nasia, blood was collected via cardiac puncture, and a few 
drops were used to determine blood triglycerides and 
cholesterol concentration using a calibrated Accutrend 
triglyceride and cholesterol meter (Roche, Mannheim, 
Germany) according to the manufacturer’s instructions. 
Thereafter, the plasma was harvested and used to deter-
mine the leptin and insulin concentrations. 
The liver was divided into two halves. One-half was 
stored at −20oC for the determination of liver lipid con-
tent. The other half of the liver used for histology analy-
sis was preserved in 10% phosphate-buffered formalin 
and later stained with haematoxylin and eosin. Liver 
slides were scored using the NAFLD activity score (NAS) 
criteria, which is a semi-quantitative grading and scoring 
system, was used to evaluate the progression and sever-
ity of NAFLD: steatosis grade 0: <5%, 1: 5% to 33%, 2: 
34∼66%, and 3: >66%; foci of lobular inflammation 
scoring 0: none, 1: <2, 2: 2∼4, and 3: >4; hepatocel-
lular ballooning scoring 0: none, 1: few ballooned cells, 
and 2: many ballooned cells (21).
Liver lipid content determination: The total liver lipid (ether 
extract) content was determined by the soxhlet method 
of extraction as described by the Association of Official 
Analytical Chemists (AOAC) 2005; method number 
920.39 (22). 
Determination of plasma insulin and leptin concentration: Plas-
ma insulin and leptin concentrations were determined 
by the sandwich enzyme-linked immunosorbent assay 
(ELISA) using a rat leptin kit [rat LEP (leptin) ELISA kit 
(sensitivity range: 0.03∼8.00 ng/mL), ElabscienceⓇ, 
Wuhan, Hubei, China] and insulin kit [rat INS (insulin) 
ELISA kit (sensitivity range: 3.125∼200 ng/mL), Elab-
scienceⓇ] according to the manufacturer’s instructions. 
Whole-body insulin sensitivity was calculated using the 
homoeostasis model assessment of insulin resistance 
(HOMA-IR) as illustrated in the equation below:
HOMA-IR=
Fasting insulin level (ng/mL)×Fasting glucose level (mg/dL)
405
(23). To convert mmol/L fasting glucose concentration 
to mg/dL, mmol/L was multiplied by 18.01.
Statistical analysis
Parametric data are expressed as mean±standard devia-
tion (SD) and non-parametric data are expressed as me-
dian and range (min, max). The data was analysed using 
GraphPad Prism 5 software (Graph-Pad Software Inc., 
San Diego, CA, USA). Statistical significance was consi-
dered at P≤0.05. A one-way ANOVA was used to ana-
lyse body mass, blood parameters, and liver lipid content 
data followed by multiple-comparisons Bonferroni post 
hoc test. The Kruskal-Wallis test was used to analyse NAS 
data followed by multiple-comparisons Dunns post hoc 
test.
RESULTS
Fig. 2 shows induction and terminal body masses of male 
(A) and female (B) rat pups, respectively. While the rat 
pups (male and female) grew significantly [(P<0.0001) 
across treatment regimens] over the experimental period, 
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Table 2. Non-alcoholic fatty liver disease activity scores (NAS) 
of suckling male (A) and female (B) rat pups following their re-
spective treatment regimens
(A)
Parameter DH FS SAC SAC+FS
Steatosis score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Ballooning score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Lobular inflammation 
score
2 (2, 2) 2 (2, 2) 1 (1, 2) 2 (2, 3)
Total NAS 2 (2, 2) 2 (2, 2) 1 (1, 2) 2 (2, 3)
(B)
Parameter DH FS SAC SAC+FS
Steatosis score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Ballooning score 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Lobular inflammation 
score 
1 (1, 3) 1 (1, 2) 2 (2, 2) 2 (2, 2)
Total NAS 1 (1, 3) 1 (1, 2) 2 (2, 2) 2 (2, 2)
Data presented as median and range (min, max) (n=3).
DH (control), 10 mL/kg body mass per day distilled water; FS, 
10 mL/kg body mass per day 20% fructose solution (w/v); SAC, 
150 mg/kg body mass per day S-allyl cysteine; SAC+FS, 150 
mg/kg body mass per day S-allyl cysteine+10 mL/kg body mass 
per day 20% fructose solution (w/v).
Total NAS is the sum of values recorded for each category. 
<2, steatohepatitis; 3∼4, uncertain; >5, probable or definite 
steatohepatitis.
Table 1. Effect of S-allyl cysteine on glucose, triglyceride, cholesterol, leptin and insulin concentrations, HOMA-IR index and liver 
lipid content of non-fasted suckling male (A) and female (B) rat pups orally administered with fructose solution
(A)
Parameter DH FS SAC SAC+FS Significance level
Glucose (mmol/L) 6.18±0.51 6.47±0.60 6.65±0.36 6.15±0.40 n.s.
Triglycerides (mmol/L) 3.94±1.57 4.89±1.31 3.82±1.47 4.04±1.21 n.s.
Cholesterol (mmol/L) 5.26±0.78 4.70±0.59 4.45±0.41 4.70±0.68 n.s.
Leptin (ng/mL) 4.28±0.64
ab
5.21±0.61
a
4.03±1.04
ab
3.68±1.13
b
<0.05
Insulin (ng/mL) 24.78±3.25
a
35.40±9.87
ab
46.68±11.13
b
34.68±7.40
ab
<0.001
HOMA-IR 7.43±0.92
a
10.44±3.06
ab
13.70±2.94
b
9.47±2.01
a
<0.01
Liver lipid (% liver mass) 1.66±0.36 1.56±0.10 1.69±0.01 1.57±0.07 n.s.
(B)
Parameter DH FS SAC SAC+FS Significance level
Glucose (mmol/L) 6.17±0.43 6.00±0.31 5.92±0.75 6.22±0.59 n.s.
Triglycerides (mmol/L) 4.36±1.34 4.16±0.82 3.63±0.76 4.08±1.18 n.s.
Cholesterol (mmol/L) 5.09±0.68 4.95±0.63 5.27±0.75 4.88±0.80 n.s.
Leptin (ng/mL) 3.87±0.26
b
3.24±0.10
b
4.75±0.68
a
4.67±0.35
a
<0.05
Insulin (ng/mL) 35.66±10.63
b
25.50±4.14
a
44.96±7.40
b
38.76±6.34
b
<0.01
HOMA-IR 10.60±0.97
b
6.80±1.43
a
11.99±2.03
b
11.13±1.94
b
<0.01
Liver lipid (% liver mass) 1.58±0.14
c
1.36±0.11
b
1.97±0.04
d
1.24±0.07
ab
<0.001
Data presented as mean±SD (n=6∼8).
DH (control), 10 mL/kg body mass per day distilled water; FS, 10 mL/kg body mass per day 20% fructose solution (w/v); SAC, 
150 mg/kg body mass per day S-allyl cysteine; SAC+FS, 150 mg/kg body mass per day S-allyl cysteine+10 mL/kg body mass 
per day 20% fructose solution (w/v); HOMA-IR, homoeostasis model assessment of insulin resistance; n.s., not significant.
Different letters (a-d) are significantly different at P≤0.05 by multiple-comparisons Bonferroni post hoc test.
their induction and terminal body masses across treat-
ment regimens were similar.
Table 1 shows non-fasted blood glucose, triglyceride, 
cholesterol, plasma leptin and insulin concentrations, and 
HOMA-IR indices of male (A) and female (B) rat pups. In 
male rat pups, the oral administration of SAC only sig-
nificantly increased plasma insulin concentration when 
compared to the control (P=0.0006). Additionally, male 
rats to which SAC only was orally administered had sig-
nificantly higher HOMA-IR compared to their counter-
parts to which the control (DH) and or test treatment 
regimen SAC+FS were administered (P=0.0009 and P= 
0.0157, respectively). In female rat pups, the oral admin-
istration of FS alone significantly lowered plasma insulin 
concentration and HOMA-IR (P<0.01). Orally adminis-
tered SAC prevented the FS-induced decrease in plasma 
insulin in female rat pups. 
Oral administration of FS alone or a combination of 
SAC+FS significantly decreased the liver lipid content of 
female rat pups (P<0.001). However, oral administration 
of SAC only significantly increased liver lipid in female 
rat pups (P<0.001) (Table 1). 
Table 2 shows the male (A) and female (B) rat pups’ 
NAS. The treatment regimens had no effect on the NAS 
of male and female rat pups. Fig. 3 shows representative 
liver histology photo sections (hematoxylin and eosin 
staining, 400× magnification) of male (A) and female (B) 
rat pups. There were no histological differences in the 
liver samples of male and female rat pups across treat-
ment regimens. 
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Fig. 3. Liver histology (hematoxylin and eosin staining, 400× magnification) of suckling male (A) and female (B) rats following 
the treatment regimens. Circle B shows foci of lobular inflammation, arrows C and D point to central veins and sinusoids respec-
tively. No histological or pathological differences were noted in the liver samples from male and female rats across treatment 
regimens. DH (control), 10 mL/kg body mass per day distilled water; FS, 10 mL/kg body mass per day 20% fructose solution 
(w/v); SAC, 150 mg/kg body mass per day S-allyl cysteine; SAC+FS, 150 mg/kg body mass per day S-allyl cysteine+10 mL/kg body 
mass per day 20% fructose solution (w/v).
DISCUSSION
Fructose feeding during early postnatal life is associated 
with derangements such as altered growth, obesity, MetS, 
DM II, and NAFLD immediately in childhood or later in 
adulthood (8). In the current study, the oral administra-
tion of FS in female rat pups resulted in hypoinsuline-
mia, while the combined oral administration of SAC and 
FS resulted in normal insulin concentration in female rat 
pups insulin, which suggests that SAC attenuated the 
FS-induced hypoinsulinemia. The oral administration of 
SAC alone resulted in increased plasma insulin concen-
tration in male rat pups suggesting that SAC possesses 
insulinotropic properties. SAC has been shown to pos-
sess antihyperglycaemic, insulinotropic, and antihyper-
lipidaemic properties in STZ-diabetic rats and high-fat 
diet NAFLD rat models (14,17,24). The mechanisms by 
which SAC exerts these beneficial properties have been 
attributed to its ability to stimulate insulin secretion by 
pancreatic β-cells, promote regeneration and longevity of 
pancreatic β-cells, and upregulate lipolytic genes and en-
zymes in the liver (17,24).
In the current study, none of the treatments regimens 
had an effect on growth performance (terminal body 
mass) of the male and female rat pups. This finding sug-
gests that the orally administered FS, SAC, or SAC+FS 
had no adverse effects on body mass or growth of male 
and female rat pups. Ghezzi et al. (25) and de Moura et 
al. (26) contend that younger rats have reduced adipos-
ity and more efficient GLUT4 transporters compared to 
their older counterparts and are more resistant to diet-in-
duced MetS. In the current study, there were similarities 
in blood glucose, triglyceride, and cholesterol concentra-
tions of male and female rat pups across treatment regi-
mens. These findings suggest that orally administered 
treatments (FS, SAC, or SAC+FS) did not result in glu-
cose, triglyceride, and cholesterol related metabolic dis-
turbances in male and female rat pups. In the current 
study, suckling rat pups were used, thus the absence of 
derangements in glucose, triglyceride, and cholesterol 
could have been attributed to resistance to diet-induced 
MetS due to reduced adiposity and the effectiveness of 
GLUT4 transporters, despite FS having been orally ad-
ministered to them. 
While insulin, a metabolic regulatory hormone, stim-
ulates glucose uptake, glycogenesis and lipogenesis and 
inhibits lipolysis in tissues, leptin inhibits satiety (27, 
28). In the current study, orally administered FS alone 
resulted in decreased plasma insulin concentrations and 
HOMA-IR in female rat pups. These findings suggest 
that the orally administered FS may have resulted in an-
ti-insulinotropic effects or increased insulin sensitivity in 
female rat pups. To our knowledge, no study has yet doc-
umented decreased plasma insulin in rats following fruc-
tose feeding. It is thus our assertion that at this moment 
the mechanisms by which orally administered FS lowered 
female rat pups plasma insulin are unknown. However, 
Teff et al. (28) reported that a high-fructose diet reduced 
circulating plasma insulin concentrations in normal- 
weight human adult females by decreasing leptin and dys-
regulating satiety. In the current study, the plasma lep-
tin concentration of female rat pups to which FS was or-
ally administered was not different compared to female 
rat pups in the other treatment regimens. Thus suggest-
ing that that the FS did not reduce insulin concentration 
in the female rats via dysregulation of satiety and other 
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leptin linked pathways. The current study was conducted 
during the early postnatal period, which is characterized 
by progressive maturation of the endocrine system such 
as the increase in pancreatic β-cells proliferation and se-
cretory function (29). We also propose that the orally ad-
ministered FS may have reduced the insulin concentra-
tions in female rats by interfering with the proliferation 
of pancreatic β-cells. Nevertheless, to gain better clarity, 
the potential mechanisms involved require further inter-
rogation. 
The current study reports that orally administered SAC 
attenuated the FS-induced hypoinsulinemia in female rat 
pups, which suggests that SAC attenuated the anti-insu-
linotropic effects of FS in female rat pups. This finding is 
in agreement with the reported SAC-mediated (as a sec-
retagogue) attenuation of hypoinsulinemia in STZ-dia-
betic adult rats (13,24). In the current study, the oral ad-
ministration of SAC only significantly increased plasma 
insulin concentration and HOMA-IR in male rat pups. 
Our findings suggest that SAC exerted insulinotropic ef-
fects and caused insulin resistance in male rat pups. The 
mechanisms by which SAC attenuated the insulin-low-
ering effects of FS in female rat pups and increased plas-
ma insulin concentration and increased HOMA-IR in 
male rat pups may be attributed to its (SAC’s) ability to 
stimulate insulin secretion by pancreatic β-cells and pre-
vent hepatic insulin inactivation (13,24). 
Excessive accumulation of hepatic lipids is associated 
with hypertriglyceridemia, hypercholesterolemia, and the 
onset of NAFLD (30). Whereas total liver lipid content 
provides an indication of the total amount of lipid sub-
strates (triglycerides, total cholesterol, and lipoproteins) 
in the liver, the NAS evaluates the progression and se-
verity NAFLD (21). In female rat pups, our results show 
that orally administered SAC increased liver lipid content 
without affecting liver histology and NAS. These find-
ings suggest that although the orally administered SAC 
may have altered hepatic lipid accretion, it did not cause 
NAFLD in the female rat pups. Our findings are in dis-
agreement with those of Saravanan and Ponmurugan 
(16) who reported that the oral administration of 150 
mg/kg SAC to STZ-diabetic male adult rats for 45 days 
attenuated hepatic hyperlipidaemia (hypercholesterole-
mia, hypertriglyceridemia, and elevated free fatty acids). 
However this difference in our findings compared to 
those by Saravanan and Ponmurugan (16) could be at-
tributed to the differences in age of the rats used (suck-
ling rats in the current study versus adult rats) and the 
duration of intervention (15 days used by the current 
study versus 45 days). Koopmans et al. (31) reported that 
in adult Sprague-Dawley rats, hyperinsulinemia stimu-
lated de novo lipogenesis, inhibited glycogenesis, and trig-
gered insulin resistance. We thus hypothesise that the 
changes in liver lipid content in female rat pups and in-
sulin sensitivity (as indicated by HOMA-IR) in male rat 
pups to which SAC only was orally administered may be 
ascribed to the potential insulinotropic effects of SAC as 
reported by the current study and other previous studies 
(13,14,24). Although our findings point to the potential 
health beneficial insulinotropic effects of SAC, it could 
potentially cause adverse metabolic effects typified by 
excessive hepatic lipid accretion in suckling female rats 
and insulin resistance in male rats. Excessive accretion of 
liver lipids and or insulin resistance increases the risk of 
developing various metabolic derangements such as MetS 
and NAFLD. 
Currently, we are unable to explain the sexually dimor-
phic responses to the interventions that were observed 
in the current study. We speculate that they could be at-
tributed to the dissimilarities in the rate and pattern of 
early life development of male and female rats (32,33). 
However, our theory warrants further investigation to ful-
ly understand the physiological mechanisms involved in 
the sexually dimorphic responses of rats. Furthermore, 
future studies need to investigate the molecular mechan-
isms, such as gene, protein, and receptor expression that 
may have been involved in the findings of the current 
study.
In conclusion, orally administered SAC protected suck-
ling female rat pups against FS-induced hypoinsulinemia 
and had insulinotropic effects in male rat pups. While 
SAC displayed potential insulinotropic effects and could 
potentially be used as an antidiabetic agent, its use should 
be done with caution as it might potentially result in fat-
ty liver disease and insulin resistance in growing rats. 
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